Money Matters with Hongbin Jeong and Chua Tian Tian (4pm - 7pm)Under the Radar: Southeast Asia’s first and only precision gut microbiome company AMILI on business verticals of microbiome sequencing and intervention; Global digestive health market to reach US$104b by 2032; Expanding research scope to look at patients undergoing cancer therapy; Funding from East Ventures; Expansion into Indonesia
Studying the microorganisms in our gut and developing solutions to address health issues and developing probiotics supplements – that is what we’re going to talk about today.
Our guest for today is AMILI. The company says it is Southeast Asia’s first and only precision gut microbiome company and houses the region’s first and only gut microbiome transplant bank.
It is also in the process of building the world’s largest multi-ethnic Asia gut microbiome database. The data is used for research and for developing products and services that improve people’s gut health.
This is apparently a lucrative market. According to Market.us, the global digestive health market is estimated to be valued at US$104.4 billion by 2032, growing by a compound annual growth rate of 8.2% during the forecast period of 2023 to 2032.
But how big is the market in Southeast Asia and how does AMILI intend to position itself to maximise growth and profits?
Had a fruitful chat with Dr Jeremy Lim, CEO and Co-founder, AMILI for more.
